This NIHR Collection brings together major studies on the prevention and treatment of childhood eczema. It finds that many ...

Once-daily roflumilast cream 0.05% is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according ...

Contrary to some commonly held beliefs, current research shows that cutting out certain foods makes little difference in ...

Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease ...

Dupilumab is safe and efficacious for the treatment of atopic dermatitis for 3 years among pediatric patients aged 6 months to 11 years.

Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of ...

Despite multiple treatments for eczema and pityriasis alba, a child’s skin condition worsened until a biopsy revealed mycosis fungoides.

NIH researchers define diagnostic criteria for topical steroid withdrawal (TSW), distinguishing it from eczema.

Discussions centered on mitigating the financial burden of pediatric atopic dermatitis through financial aid programs and enhancing support for young patients to independently manage their condition ...

Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic ...

After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...

Once-daily roflumilast cream 0.05 percent is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 ye ...